Kaposi Sarcoma Market: Popular Trends & Technological advancements to Watch Out for Near Future; Global Industry Analysis 2020 Date: 03-09-2017 07:22 PM CET Category: Health & Medicine Press release from: Transparency Market Research - Pharmaceutical
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs. Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President’s Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing. Download Exclusive Brochure of This Report : www.transparencymarketresearch.com/sample/sample.php?flag... High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. “Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection,” the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population. The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.
Seite 1 / 3